John Fallon Biography and Net Worth

Director of Insulet


Dr. John A. Fallon M.D. serves as Independent Director of the Company. From 2004 until January 2016, Dr. Fallon served as Senior Vice President and Chief Physician Executive at Blue Cross & Blue Shield of Massachusetts (“BCBS”). Prior to his role at BCBS, Dr. Fallon served as Chief Executive Officer for clinical affairs at the State University of New York Downstate Medical Center, including University Hospital of Brooklyn and the clinical faculty practice plan. His professional experience also includes the Partners Healthcare System, where he was chairman of the physician network. Dr. Fallon was also the founder and Chief Executive Officer of North Shore Health System, a large physician-hospital organization in Massachusetts. He has served on the Board of Directors of Insulet Corporation, a public medical devices company, since 2012 and as the lead independent director from February 2015 to August 2016 and currently serves as the Chair of the Nominating, Governance and Risk Committee. In addition, Dr. Fallon has been a member of the Board of Directors of Exact Sciences Corporation, a public molecular diagnostics company, since January 2016 where he is also a member of the Audit Committee and Nominating and Governance Committee. Dr. Fallon has also served on the Board of Directors of Collegium Pharmaceutical Inc., a public pharmaceutical company, since June 2016 where he is also a member of the Audit Committee and the Nominating and Governance Committee. Dr. Fallon also serves on NEHI (Network for Excellence in Health Innovation) (Chair), a non-profit board. Dr. Fallon practiced internal medicine for more than 20 years, fulfilled his residency at Boston City Hospital, is Board Certified in Internal Medicine and is a fellow of the American College of Physicians. He received a B.A. in chemistry from the College of the Holy Cross, an M.B.A from the University of South Florida and a medical degree from Tufts University School of Medicine.

What is John A. Fallon's net worth?

The estimated net worth of John A. Fallon is at least $3.17 million as of November 2nd, 2020. Dr. Fallon owns 18,498 shares of Insulet stock worth more than $3,170,557 as of March 29th. This net worth approximation does not reflect any other investments that Dr. Fallon may own. Learn More about John A. Fallon's net worth.

How do I contact John A. Fallon?

The corporate mailing address for Dr. Fallon and other Insulet executives is 100 NAGOG PARK, ACTON MA, 01720. Insulet can also be reached via phone at (978) 600-7000 and via email at [email protected]. Learn More on John A. Fallon's contact information.

Has John A. Fallon been buying or selling shares of Insulet?

John A. Fallon has not been actively trading shares of Insulet during the past quarter. Most recently, John A. Fallon sold 4,000 shares of the business's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $225.00, for a transaction totalling $900,000.00. Following the completion of the sale, the director now directly owns 18,498 shares of the company's stock, valued at $4,162,050. Learn More on John A. Fallon's trading history.

Who are Insulet's active insiders?

Insulet's insider roster includes Charles Alpuche (COO), Eric Benjamin (SVP), Luciana Borio (Director), Bret Christensen (EVP), Sally Crawford (Director), John Fallon (Director), James Hollingshead (CEO), Dan Manea (SVP), Wayde McMillan (CFO), Shacey Petrovic (CEO), Prem Singh (SVP), and Michael Spears (SVP). Learn More on Insulet's active insiders.

Are insiders buying or selling shares of Insulet?

In the last twelve months, Insulet insiders bought shares 2 times. They purchased a total of 5,551 shares worth more than $1,006,994.42. In the last twelve months, insiders at the medical instruments supplier sold shares 7 times. They sold a total of 49,927 shares worth more than $10,235,978.05. The most recent insider tranaction occured on February, 28th when Director Shacey Petrovic sold 11,609 shares worth more than $1,891,338.28. Insiders at Insulet own 0.9% of the company. Learn More about insider trades at Insulet.

Information on this page was last updated on 2/28/2024.

John A. Fallon Insider Trading History at Insulet

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/2/2020Sell4,000$225.00$900,000.0018,498View SEC Filing Icon  
11/18/2019Sell14,525$181.21$2,632,075.25
3/20/2019Sell5,000$100.00$500,000.00View SEC Filing Icon  
3/12/2019Sell5,000$95.00$475,000.00View SEC Filing Icon  
3/6/2019Sell10,000$92.64$926,400.00View SEC Filing Icon  
3/14/2018Sell9,000$84.10$756,900.00View SEC Filing Icon  
See Full Table

John A. Fallon Buying and Selling Activity at Insulet

This chart shows John A Fallon's buying and selling at Insulet by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Insulet Company Overview

Insulet logo
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Read More

Today's Range

Now: $171.40
Low: $169.22
High: $172.21

50 Day Range

MA: $182.81
Low: $163.60
High: $206.03

2 Week Range

Now: $171.40
Low: $125.82
High: $335.91

Volume

786,601 shs

Average Volume

889,404 shs

Market Capitalization

$11.99 billion

P/E Ratio

58.90

Dividend Yield

N/A

Beta

0.98